1. Short title This Act may be cited as the Protecting Patient Access to Cancer and Complex Therapies Act of 2023 . 2. Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation (a) Maintaining payments under part B based on ASP+6 Section 1847A(b)(1)(B) of the Social Security Act (42 U.S.C. 1395w–3a(b)(1)(B)) is amended by striking or in the case of such a drug or biological product that is a selected drug and all that follows through the semicolon and inserting a semicolon. (b) Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation (1) In general Section 1847A of the Social Security Act ( 42 U.S.C. 1395w–3a ) is amended— (A) by redesignating subsection (j) as subsection (k); and (B) by inserting after subsection (i) the following new subsection: (j) Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation (1) Requirements (A) Secretarial provision of information Not later than 6 months after the end of each calendar quarter beginning on or after the first day of the initial price applicability period (as defined in section 1191(b)(2)), the Secretary shall, for each selected drug (as defined in section 1192(c)) of each manufacturer with an agreement under section 1193 for which a maximum fair price is in effect and for which payment may be made under this part, report to each manufacturer of such selected drug the following for such calendar quarter during such price applicability period: (i) Information on the total number of units of the billing and payment code for such selected drug furnished under this part during such calendar quarter. (ii) Information on the sum of— (I) the amount (if any) by which— (aa) the ASP+6 payment amount (as defined in paragraph (5)) for such drug and calendar quarter, less the ASP+6 coinsurance amount for such drug and calendar quarter